NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis → Why Is Gold On a MASSIVE rally? (From Huge Alerts) (Ad) Free KYTX Stock Alerts $15.42 +0.17 (+1.11%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$14.85▼$15.9550-Day Range$12.66▼$30.0852-Week Range$12.26▼$35.06Volume280,858 shsAverage Volume396,746 shsMarket Capitalization$664.91 millionP/E RatioN/ADividend YieldN/APrice Target$42.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get Kyverna Therapeutics alerts: Email Address Kyverna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside177.2% Upside$42.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.26) to ($4.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector630th out of 922 stocksBiological Products, Except Diagnostic Industry100th out of 155 stocks 4.5 Analyst's Opinion Consensus RatingKyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKyverna Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kyverna Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KYTX. Previous Next 0.0 Dividend Strength Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KYTX. Previous Next 2.3 News and Social Media Coverage News SentimentKyverna Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Kyverna Therapeutics this week, compared to 5 articles on an average week.Search Interest6 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.26) to ($4.07) per share.Price to Book Value per Share RatioKyverna Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kyverna Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyPOTUS in ‘25 Not Biden/Trump, ButAnd I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. About Kyverna Therapeutics Stock (NASDAQ:KYTX)Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Read More KYTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KYTX Stock News HeadlinesMay 16 at 11:05 AM | markets.businessinsider.comBuy Rating for Kyverna Therapeutics Based on KYV-101’s Clinical Progress and Financial StabilityMay 16 at 11:05 AM | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics Amidst Positive Clinical Trials and Manufacturing AdvancementsMay 15 at 7:02 PM | msn.comKyverna Therapeutics reports Q1 GAAP EPS of -$1.12May 15 at 12:06 AM | investorplace.comKYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024May 14 at 4:05 PM | prnewswire.comKyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 11, 2024 | americanbankingnews.comComparing Kyverna Therapeutics (NASDAQ:KYTX) & Sana Biotechnology (NASDAQ:SANA)May 8, 2024 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) vs. Kyverna Therapeutics (NASDAQ:KYTX) Financial ContrastApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Drug Efficacy and Safety DataApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Clinical AdvancesApril 11, 2024 | finance.yahoo.comKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesApril 11, 2024 | prnewswire.comKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesApril 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising Early-Stage KYV-101 Results for MS TreatmentMarch 29, 2024 | finance.yahoo.comFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedMarch 29, 2024 | prnewswire.comFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedMarch 29, 2024 | markets.businessinsider.comBuy Recommendation: Kyverna Therapeutics’ Innovative Autoimmune Cell Therapy and Robust Pipeline Promise Market LeadershipMarch 27, 2024 | finance.yahoo.comKyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 14, 2024 | finance.yahoo.comWhy That Hot Biotech IPO Could Be a WinnerMarch 7, 2024 | markets.businessinsider.comKyverna, Stanford University To Evaluate KYV-101 In Non-Relapsing & Progressive Forms Of MSMarch 7, 2024 | finance.yahoo.comHow Kyverna is positioned for success on autoimmune therapy: CEOFebruary 27, 2024 | morningstar.comKyverna Therapeutics Inc KYTXFebruary 27, 2024 | investing.comKyverna Therapeutics Inc (KYTX)February 26, 2024 | msn.comEveryone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?February 26, 2024 | finance.yahoo.comKyverna Therapeutics Announces Pricing of Upsized Initial Public OfferingFebruary 26, 2024 | finance.yahoo.comKyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesSee More Headlines Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CUSIPN/A CIK1994702 Webkyvernatx.com Phone510-626-8331FaxN/AEmployees96Year FoundedN/APrice Target and Rating Average Stock Price Target$42.75 High Stock Price Target$48.00 Low Stock Price Target$39.00 Potential Upside/Downside+177.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio17.17 Quick Ratio3.05 Sales & Book Value Annual Sales$7.03 million Price / Sales94.58 Cash FlowN/A Price / Cash FlowN/A Book Value$8.37 per share Price / Book1.84Miscellaneous Outstanding Shares43,120,000Free FloatN/AMarket Cap$664.91 million OptionableOptionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Peter Maag Ph.D. (Age 57)CEO & Director Comp: $709.99kMs. Karen Walker (Age 62)Chief Technology Officer Comp: $561.64kDr. James Chung M.D. (Age 56)Ph.D., Chief Medical Officer Comp: $645.62kDr. Tom Van Blarcom Ph.D.Senior VP & Head of ResearchMs. Portia SerameVice President of Human ResourcesDr. Dominic Borie M.D. (Age 61)Ph.D., President of Research & Development Mr. Devin MurraySenior Vice President of Partnerships & AlliancesMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSExscientiaNASDAQ:EXAIValnevaNASDAQ:VALNCabaletta BioNASDAQ:CABAHilleVaxNASDAQ:HLVXView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 200,000 shares on 5/17/2024Ownership: 0.464%Bain Capital Life Sciences Investors LLCBought 3,163,868 shares on 5/16/2024Ownership: 7.338%Janus Henderson Group PLCBought 606,500 shares on 5/16/2024Ownership: 1.407%Blackstone Inc.Bought 100,000 shares on 5/16/2024Ownership: 0.232%Avoro Capital Advisors LLCBought 475,000 shares on 5/15/2024Ownership: 1.102%View All Insider TransactionsView All Institutional Transactions KYTX Stock Analysis - Frequently Asked Questions Should I buy or sell Kyverna Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kyverna Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KYTX shares. View KYTX analyst ratings or view top-rated stocks. What is Kyverna Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued 1 year price targets for Kyverna Therapeutics' stock. Their KYTX share price targets range from $39.00 to $48.00. On average, they expect the company's stock price to reach $42.75 in the next twelve months. This suggests a possible upside of 177.2% from the stock's current price. View analysts price targets for KYTX or view top-rated stocks among Wall Street analysts. How have KYTX shares performed in 2024? Kyverna Therapeutics' stock was trading at $30.10 at the beginning of 2024. Since then, KYTX shares have decreased by 48.8% and is now trading at $15.42. View the best growth stocks for 2024 here. When is Kyverna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our KYTX earnings forecast. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.28. During the same period in the previous year, the business earned ($12.10) EPS. What ETF holds Kyverna Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,187 shares of KYTX stock, representing 0.44% of its portfolio. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share. When did the company's quiet period expire? Kyverna Therapeutics' quiet period expired on Tuesday, March 19th. Kyverna Therapeutics had issued 14,500,000 shares in its initial public offering on February 8th. The total size of the offering was $319,000,000 based on an initial share price of $22.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Kyverna Therapeutics' major shareholders? Kyverna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (7.34%), Jennison Associates LLC (3.24%), Price T Rowe Associates Inc. MD (2.16%), Janus Henderson Group PLC (1.41%), Avoro Capital Advisors LLC (1.10%) and Vanguard Group Inc. (0.61%). View institutional ownership trends. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KYTX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.